Associated Banc Corp Has $13.30 Million Holdings in Danaher Corporation $DHR

Associated Banc Corp reduced its stake in Danaher Corporation (NYSE:DHR) by 3.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,310 shares of the conglomerate’s stock after selling 2,326 shares during the quarter. Associated Banc Corp’s holdings in Danaher were worth $13,296,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in DHR. White Pine Capital LLC boosted its position in shares of Danaher by 1.4% during the second quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock worth $690,000 after buying an additional 49 shares during the period. Boyd Watterson Asset Management LLC OH boosted its position in Danaher by 2.1% during the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock worth $499,000 after acquiring an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC grew its stake in shares of Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after acquiring an additional 53 shares in the last quarter. 1834 Investment Advisors Co. raised its holdings in shares of Danaher by 3.3% in the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 54 shares during the last quarter. Finally, Bruce G. Allen Investments LLC lifted its position in shares of Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after purchasing an additional 54 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE DHR opened at $227.05 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The firm has a market cap of $160.38 billion, a price-to-earnings ratio of 46.81, a P/E/G ratio of 3.28 and a beta of 0.81. The stock’s fifty day moving average price is $209.36 and its two-hundred day moving average price is $202.34. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23.

Danaher (NYSE:DHR) last announced its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter in the previous year, the business posted $1.71 earnings per share. Danaher’s quarterly revenue was up 4.4% on a year-over-year basis. On average, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio is presently 26.39%.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 3,298 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the transaction, the director owned 20,762 shares in the company, valued at $4,702,593. This trade represents a 13.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 30,248 shares of company stock valued at $6,609,663. 11.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on DHR shares. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research note on Tuesday, September 2nd. TD Cowen upped their target price on Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a research note on Wednesday, October 8th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.